Business Context and Reporting Period
Company: Alpha Pro Tech, Ltd.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2004
Business Overview: The company manufactures and distributes disposable protective apparel, infection control products (masks/shields), extended care products, and consumer goods (pet beds). A new "Engineered Products" segment (construction weatherization and antimicrobial paint) was formed in June 2004 but had not yet generated sales by the period end.
Key Financial Metrics
| Metric | 3 Months Ended Sep 30, 2004 | 9 Months Ended Sep 30, 2004 |
|---|---|---|
| Sales (Revenue) | $5,827,000 | $18,428,000 |
| Gross Margin | $2,917,000 (50.1%) | $9,147,000 (49.6%) |
| Net Income | $374,000 | $1,290,000 |
| Diluted EPS | $0.02 | $0.05 |
| Cash and Equivalents | $3,500,000 | $3,500,000 (Ending Balance) |
| Working Capital | $12,164,000 | N/A |
| Debt | $0 | $0 |
Cash Flow (9 Months): Operating activities used $154,000; Investing activities used $261,000; Financing activities provided $488,000.
Material Changes vs. Prior Period
- Revenue Decline: Sales decreased 10.6% ($690,000) for the quarter and 10.0% ($2,039,000) for the nine months compared to 2003. This is primarily due to the absence of approximately $0.5 million (quarter) and $3.5 million (nine months) in non-core SARS-related mask sales recorded in 2003.
- Core Business Growth: Excluding SARS-related sales, core business sales increased 3.2% for the quarter and 8.6% for the nine months, driven by growth in the Apparel segment (pharmaceutical/cleanroom markets).
- Profitability: Net income decreased 46.6% for the quarter and 49.1% for the nine months. The decline is attributed to lower gross margins (due to the loss of high-margin SARS sales), increased SG&A expenses, and start-up costs for the new Engineered Products segment ($155,000 in Q3; $180,000 for 9 months).
- Segment Performance:
- Apparel: Sales increased 3.3% (Q3) and 14.1% (9M).
- Mask and Shield: Sales decreased 43.4% (Q3) and 49.0% (9M) due to the drop in SARS demand.
- Extended Care: Sales increased 5.6% (Q3) and 9.8% (9M), driven by pet bed sales.
Outlook, Risks, and Management Commentary
- Outlook: Management expects the new Engineered Products segment to begin manufacturing and distribution in Q4 2004, contributing significantly to revenue growth in 2005. Core business growth is expected to continue as the company gains market share in pharmaceutical and cleanroom sectors.
- Liquidity: The company maintains a $3.5 million credit facility (prime + 0.5%) with $2,996,000 available capacity. No borrowings were outstanding as of September 30, 2004. Management believes current cash and credit facilities are sufficient for foreseeable needs.
- Capital Allocation: The Board authorized an additional $500,000 share repurchase program in August 2004. During the nine months ended September 30, 2004, the company repurchased 215,000 shares for $371,000.
- Risks:
- Foreign Currency: Operations in China and Mexico expose the company to exchange rate fluctuations, though no hedging is currently employed.
- Start-up Costs: The new Engineered Products segment incurred significant start-up costs in 2004, impacting short-term profitability.
Investor Verification Checklist
- SARS Impact: Verify the sustainability of core sales growth by excluding the one-time SARS-related revenue from 2003 comparisons.
- Engineered Products Viability: Monitor the Q4 2004 launch of the new Engineered Products segment and its ability to offset start-up costs and drive 2005 revenue.
- Cash Flow Trends: Review the shift from positive operating cash flow in 2003 to negative operating cash flow in 2004 ($154,000 used) to ensure working capital management remains stable.
- Inventory Levels: Note that inventory decreased by $853,000 during the nine-month period, which contributed to cash flow but should be monitored against sales velocity.